Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

Richard A. Larson, Ophelia Qi Ping Yin, +8 authors Philipp D. le Coutre
Published 2011 in European Journal of Clinical Pharmacology

Abstract

We investigated the population pharmacokinetics and exposure-response relationship of nilotinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase. Nilotinib was given at 300 mg or 400 mg twice daily. Serum concentration data (sparse and full pharmacokinetic profiles) were obtained from 542 patients over 12 months. A population… (More)

DOI: 10.1007/s00228-011-1200-7

Topics

10 Figures and Tables

Cited By

Sort by:

Dmd059097 1851..1857

Rosie A. Johnston, Tristan Rawling, Ting Chan, Fanfan Zhou, Michael Murray
2014

A validated UPLC–MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma

Jing Zeng, Hua lin Cai, +4 authors Xie lan Zhao
Journal of pharmaceutical analysis
2017

Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review

Andreu Porta‐Sánchez, Cameron Gilbert, +4 authors Paaladinesh Thavendiranathan
Journal of the American Heart Association
2017

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Remy B. Verheijen, Huixin Yu, Jan H.M. Schellens, Jos H. Beijnen, Neeltje Steeghs, Alwin D.R. Huitema
Clinical pharmacology and therapeutics
2017

Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma

Hiroshi Kato, Naoto Sassa, +6 authors Kiyofumi Yamada
Cancer Chemotherapy and Pharmacology
2016

Possible FDA-approved drugs to treat Ebola virus infection

Shu Yuan
Infectious diseases of poverty
2015

In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia

Aleksandar Radujkovic, Thomas Luft, +4 authors Julian Topaly
Cancer Chemotherapy and Pharmacology
2014

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib

Naoto Takahashi, Masatomo Miura, +27 authors Kenichi Sawada
Biomarker Research
2014

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Michele Baccarani, Michael W Deininger, +29 authors Rüdiger Hehlmann
Blood
2013

Playing Russian roulette with tyrosine kinase inhibitors.

R Z Szmulewitz, M J Ratain
Clinical pharmacology and therapeutics
2013

References

Sort by:

Showing 1-10 of 29 references

RA Larson, A Hochhaus, +11 authors HM Kantarjian
[abstract
2010

Extended kinase profile and properties of the protein kinase inhibitor nilotinib.

Paul W Manley, Peter Drueckes, +7 authors Doriano Fabbro
Biochimica et biophysica acta
2010

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

E Weisberg, P Manley, J Mestan, S Cowan-Jacob, A Ray, J D Griffin
British Journal of Cancer
2006

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Ellen Weisberg, Paul W Manley, +18 authors James D Griffin
Cancer cell
2005

Harmonization of molecular monitoring of CML therapy in Europe

M C Müller, N C P Cross, +7 authors A Hochhaus
Leukemia
2009

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

S Branford, N C P Cross, +5 authors T Hughes
Leukemia
2006

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib.

C Tanaka, O Q P Yin, +8 authors H Schran
Clinical pharmacology and therapeutics
2010

Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants.

Ophelia Q P Yin, Neil Gallagher, Ai Li, Wei Zhou, Robert Harrell, Horst Schran
Journal of clinical pharmacology
2010

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.

Jorge E Cortes, Dan Jones, +8 authors Hagop Kantarjian
Journal of clinical oncology : official journal…
2010

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Giuseppe Saglio, Dong-Wook Kim, +13 authors Hagop M Kantarjian
The New England journal of medicine
2010

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

Abstract

Topics

10 Figures and Tables

Cited By

Dmd059097 1851..1857

A validated UPLC–MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma

Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma

Possible FDA-approved drugs to treat Ebola virus infection

In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Playing Russian roulette with tyrosine kinase inhibitors.

References

Cardiac safety profile of imatinib and nilotinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): results from ENESTnd

Extended kinase profile and properties of the protein kinase inhibitor nilotinib.

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Harmonization of molecular monitoring of CML therapy in Europe

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib.

Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants.

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Slides referencing similar topics

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

Abstract

Topics

10 Figures and Tables

Cited By

Dmd059097 1851..1857

A validated UPLC–MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma

Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma

Possible FDA-approved drugs to treat Ebola virus infection

In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Playing Russian roulette with tyrosine kinase inhibitors.

References

Cardiac safety profile of imatinib and nilotinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): results from ENESTnd

Extended kinase profile and properties of the protein kinase inhibitor nilotinib.

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Harmonization of molecular monitoring of CML therapy in Europe

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib.

Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants.

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Similar Papers

Slides referencing similar topics